DORCHESTER WEALTH MANAGEMENT Co Sells 300 Shares of Merck & Co., Inc. (NYSE:MRK)

DORCHESTER WEALTH MANAGEMENT Co decreased its position in Merck & Co., Inc. (NYSE:MRKFree Report) by 2.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 10,088 shares of the company’s stock after selling 300 shares during the period. DORCHESTER WEALTH MANAGEMENT Co’s holdings in Merck & Co., Inc. were worth $1,100,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Moneta Group Investment Advisors LLC boosted its holdings in shares of Merck & Co., Inc. by 103,159.7% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 39,327,490 shares of the company’s stock worth $4,363,385,000 after acquiring an additional 39,289,404 shares during the period. Norges Bank acquired a new stake in Merck & Co., Inc. in the fourth quarter valued at $2,736,293,000. Wellington Management Group LLP boosted its position in Merck & Co., Inc. by 6.7% during the third quarter. Wellington Management Group LLP now owns 82,442,666 shares of the company’s stock valued at $8,487,472,000 after acquiring an additional 5,196,914 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Merck & Co., Inc. by 2,671.4% during the 1st quarter. Renaissance Technologies LLC now owns 5,099,334 shares of the company’s stock worth $418,400,000 after purchasing an additional 4,915,334 shares in the last quarter. Finally, Barclays PLC lifted its position in Merck & Co., Inc. by 184.5% in the 2nd quarter. Barclays PLC now owns 7,254,914 shares of the company’s stock valued at $837,144,000 after acquiring an additional 4,705,004 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Insider Buying and Selling

In related news, EVP Steven Mizell sold 50,694 shares of the business’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the sale, the executive vice president now owns 23,619 shares of the company’s stock, valued at $2,991,346.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Joseph Romanelli sold 1,000 shares of the firm’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $124.89, for a total transaction of $124,890.00. Following the sale, the insider now directly owns 19,569 shares in the company, valued at approximately $2,443,972.41. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Steven Mizell sold 50,694 shares of Merck & Co., Inc. stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the completion of the sale, the executive vice president now owns 23,619 shares in the company, valued at $2,991,346.35. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by insiders.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK traded up $0.50 during mid-day trading on Wednesday, reaching $130.85. 2,273,934 shares of the company were exchanged, compared to its average volume of 8,614,414. Merck & Co., Inc. has a 52 week low of $99.14 and a 52 week high of $133.10. The company has a quick ratio of 1.00, a current ratio of 1.25 and a debt-to-equity ratio of 0.89. The stock has a market capitalization of $331.40 billion, a PE ratio of 931.07, a PEG ratio of 0.52 and a beta of 0.38. The company’s 50 day moving average price is $125.45 and its 200 day moving average price is $113.20.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its earnings results on Thursday, February 1st. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.12. The company had revenue of $14.63 billion for the quarter, compared to analysts’ expectations of $14.49 billion. Merck & Co., Inc. had a net margin of 0.61% and a return on equity of 9.33%. The firm’s revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the company earned $1.62 EPS. Sell-side analysts forecast that Merck & Co., Inc. will post 8.59 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 5th. Investors of record on Friday, March 15th will be given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 2.35%. The ex-dividend date of this dividend is Thursday, March 14th. Merck & Co., Inc.’s dividend payout ratio is currently 2,200.00%.

Analysts Set New Price Targets

MRK has been the subject of several analyst reports. UBS Group increased their price objective on shares of Merck & Co., Inc. from $135.00 to $148.00 and gave the company a “buy” rating in a research note on Friday, February 2nd. Barclays raised their price target on shares of Merck & Co., Inc. from $135.00 to $145.00 and gave the stock an “overweight” rating in a research note on Friday, February 2nd. Cantor Fitzgerald restated an “overweight” rating and set a $135.00 price target on shares of Merck & Co., Inc. in a research note on Wednesday, March 27th. Wells Fargo & Company raised their price target on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 27th. Finally, TD Cowen upgraded shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $125.00 to $135.00 in a research note on Thursday, January 4th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $129.71.

Read Our Latest Stock Analysis on MRK

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Further Reading

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.